Enzo Biochem Company Insiders
ENZ Stock | USD 1.04 0.06 6.12% |
Enzo Biochem's insiders are aggressively buying. The analysis of insiders' sentiment of trading Enzo Biochem stock suggests that vertually all insiders are extremely bullish at this time. Enzo Biochem employs about 125 people. The company is managed by 19 executives with a total tenure of roughly 77 years, averaging almost 4.0 years of service per executive, having 6.58 employees per reported executive.
Elazar Rabbani Chairman Chairman of the Board, Chief Executive Officer, Secretary |
Barry Weiner President President, Chief Financial Officer, Principal Accounting Officer, Treasurer, Director |
Enzo Biochem's Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
2023-02-13 | James G Wolf | Acquired 5000 @ 1.28 | View | ||
2023-02-10 | James G Wolf | Acquired 5000 @ 1.29 | View | ||
2023-01-27 | James G Wolf | Acquired 11800 @ 1.4 | View | ||
2022-11-23 | Hamid Erfanian | Acquired 100000 @ 1.97 | View | ||
2022-07-15 | Kara Cannon | Acquired 2500 @ 2.42 | View | ||
2022-07-12 | Bradley Louis Radoff | Acquired 12500 @ 2.27 | View | ||
2022-07-05 | Bradley Louis Radoff | Acquired 120000 @ 2.2 | View | ||
2022-06-15 | Hamid Erfanian | Acquired 4600 @ 2.19 | View | ||
2022-06-14 | David Bench | Acquired 3500 @ 2.15 | View |
Monitoring Enzo Biochem's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Enzo |
Enzo Biochem Management Team Effectiveness
The company has Return on Asset of (0.0744) % which means that on every $100 spent on assets, it lost $0.0744. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.1459) %, meaning that it generated no profit with money invested by stockholders. Enzo Biochem's management efficiency ratios could be used to measure how well Enzo Biochem manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -0.29 in 2024. Return On Capital Employed is likely to drop to -0.17 in 2024. At this time, Enzo Biochem's Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 7.2 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 14.9 M in 2024.Net Income Applicable To Common Shares is likely to rise to about 19.2 M in 2024, whereas Common Stock Shares Outstanding is likely to drop slightly above 37.4 M in 2024.
Enzo Biochem Workforce Comparison
Enzo Biochem is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 9,092. Enzo Biochem claims roughly 125 in number of employees contributing just under 2% to equities under Health Care industry.
Enzo Biochem Profit Margins
The company has Net Profit Margin of (0.82) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (0.39) %, which entails that for every $100 of revenue, it lost $0.39.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.61 | 0.4586 |
|
|
Enzo Biochem Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Enzo Biochem insiders, such as employees or executives, is commonly permitted as long as it does not rely on Enzo Biochem's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Enzo Biochem insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Wolf James G. over two months ago Acquisition by Wolf James G. of 5000 shares of Enzo Biochem at 2.14 subject to Rule 16b-3 | ||
Wolf James G. over three months ago Disposition of 337 shares by Wolf James G. of Enzo Biochem subject to Rule 16b-3 | ||
Hamid Erfanian over three months ago Acquisition by Hamid Erfanian of 700000 shares of Enzo Biochem subject to Rule 16b-3 | ||
Kara Cannon over three months ago Disposition of 70885 shares by Kara Cannon of Enzo Biochem at 1.17 subject to Rule 16b-3 | ||
Kara Cannon over six months ago Acquisition by Kara Cannon of 200000 shares of Enzo Biochem at 2.0 subject to Rule 16b-3 | ||
Wolf James G. over six months ago Acquisition by Wolf James G. of 444 shares of Enzo Biochem at 1.29 subject to Rule 16b-3 | ||
Wolf James G. over six months ago Discretionary transaction by Wolf James G. of tradable shares of Enzo Biochem subject to Rule 16b-3 | ||
Kara Cannon over six months ago Acquisition by Kara Cannon of 345080 shares of Enzo Biochem subject to Rule 16b-3 |
Enzo Biochem Notable Stakeholders
An Enzo Biochem stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Enzo Biochem often face trade-offs trying to please all of them. Enzo Biochem's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Enzo Biochem's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Hamid Erfanian | Chief Executive Officer, Director | Profile | |
Elazar Rabbani | Chairman of the Board, Chief Executive Officer, Secretary | Profile | |
Barry Weiner | President, Chief Financial Officer, Principal Accounting Officer, Treasurer, Director | Profile | |
Bruce Dey | Vice President - Sales and Marketing of Enzo Clinical Labs | Profile | |
David Bench | Chief Financial Officer, Senior Vice President, Treasurer, Corporate Secretary | Profile | |
Mary Tagliaferri | Lead Independent Director | Profile | |
Dov Perlysky | Lead Independent Director | Profile | |
Ian Walters | Independent Director | Profile | |
Bruce Hanna | Independent Director | Profile | |
Dieter Schapfel | Chief Medical Director of Enzo Clinical Labs | Profile | |
Dieter MD | Chief Labs | Profile | |
Matthew Kupferberg | General Secretary | Profile | |
Peter Clemens | Director | Profile | |
Brian Fisher | General Counsel | Profile | |
Patricia CPA | Interim Officer | Profile | |
Rebecca Fischer | Independent Director | Profile | |
Fabian Blank | Director | Profile | |
Bradley Radoff | Independent Director | Profile | |
Kara Cannon | Corporate Vice President - Commercial Operations | Profile |
About Enzo Biochem Management Performance
The success or failure of an entity such as Enzo Biochem often depends on how effective the management is. Enzo Biochem management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Enzo management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Enzo management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.30) | (0.29) | |
Return On Capital Employed | (0.16) | (0.17) | |
Return On Assets | (0.30) | (0.29) | |
Return On Equity | (0.46) | (0.49) |
Please note, the imprecision that can be found in Enzo Biochem's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Enzo Biochem. Check Enzo Biochem's Beneish M Score to see the likelihood of Enzo Biochem's management manipulating its earnings.
Enzo Biochem Workforce Analysis
Traditionally, organizations such as Enzo Biochem use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Enzo Biochem within its industry.Enzo Biochem Manpower Efficiency
Return on Enzo Biochem Manpower
Revenue Per Employee | 255.3K | |
Revenue Per Executive | 1.7M | |
Net Loss Per Employee | 208.6K | |
Net Loss Per Executive | 1.4M | |
Working Capital Per Employee | 361.9K | |
Working Capital Per Executive | 2.4M |
Additional Tools for Enzo Stock Analysis
When running Enzo Biochem's price analysis, check to measure Enzo Biochem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enzo Biochem is operating at the current time. Most of Enzo Biochem's value examination focuses on studying past and present price action to predict the probability of Enzo Biochem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enzo Biochem's price. Additionally, you may evaluate how the addition of Enzo Biochem to your portfolios can decrease your overall portfolio volatility.